Literature DB >> 23624918

The molecular and cell biology of pediatric low-grade gliomas.

Y-H Chen1, D H Gutmann1.   

Abstract

Pilocytic astrocytoma (PA) is the most common glial cell tumor arising in children. Sporadic cases are associated with KIAA1549:BRAF fusion rearrangements, while 15-20% of children develop PA in the context of the neurofibromatosis 1 (NF1) inherited tumor predisposition syndrome. The unique predilection of these tumors to form within the optic pathway and brainstem (NF1-PA) and cerebellum (sporadic PA) raises the possibility that gliomagenesis requires more than biallelic inactivation of the NF1 tumor suppressor gene or expression of the KIAA1549:BRAF transcript. Several etiologic explanations include differential susceptibilities of preneoplastic neuroglial cell types in different brain regions to these glioma-causing genetic changes, contributions from non-neoplastic cells and signals in the tumor microenvironment, and genomic modifiers that confer glioma risk. As clinically-faithful rodent models of sporadic PA are currently under development, Nf1 genetically-engineered mouse (GEM) models have served as tractable systems to study the role of the cell of origin, deregulated intracellular signaling, non-neoplastic cells in the tumor microenvironment and genomic modifiers in gliomagenesis. In this report, we highlight advances in Nf1-GEM modeling and review new experimental evidence that supports the emerging concept that Nf1- and KIAA1549:BRAF-induced gliomas arise from specific cell types in particular brain locations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23624918     DOI: 10.1038/onc.2013.148

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Separation of outer retinal layers secondary to selumetinib.

Authors:  Robert A Avery; Carmelina Trimboli-Heidler; Lindsay B Kilburn
Journal:  J AAPOS       Date:  2016-04-21       Impact factor: 1.220

Review 2.  Medical therapy of gliomas.

Authors:  Manmeet S Ahluwalia; Susan M Chang
Journal:  J Neurooncol       Date:  2014-07-02       Impact factor: 4.130

Review 3.  Review of low-grade gliomas in children--evolving molecular era and therapeutic insights.

Authors:  Soumen Khatua; Jason Wang; Veena Rajaram
Journal:  Childs Nerv Syst       Date:  2015-02-27       Impact factor: 1.475

Review 4.  Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.

Authors:  John Glod; Gilbert J Rahme; Harpreet Kaur; Eric H Raabe; Eugene I Hwang; Mark A Israel
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

5.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.

Authors:  Hui Liu; Charles J Murphy; Florian A Karreth; Kristina B Emdal; Forest M White; Olivier Elemento; Alex Toker; Gerburg M Wulf; Lewis C Cantley
Journal:  Cancer Discov       Date:  2017-12-04       Impact factor: 39.397

6.  Type 1 IGF Receptor Localization in Paediatric Gliomas: Significant Association with WHO Grading and Clinical Outcome.

Authors:  Florencia Clément; Ayelen Martin; Marcela Venara; Maria de Luján Calcagno; Cecilia Mathó; Silvana Maglio; Mercedes García Lombardi; Ignacio Bergadá; Patricia A Pennisi
Journal:  Horm Cancer       Date:  2018-03-09       Impact factor: 3.869

7.  Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1.

Authors:  Robert A Avery; Awais Mansoor; Rabia Idrees; Carmelina Trimboli-Heidler; Hiroshi Ishikawa; Roger J Packer; Marius George Linguraru
Journal:  Neurology       Date:  2016-11-04       Impact factor: 9.910

Review 8.  Pediatric cerebellar astrocytoma: a review.

Authors:  Christopher M Bonfield; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

Review 9.  An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.

Authors:  Alvaro Lassaletta; Michal Zapotocky; Eric Bouffet; Cynthia Hawkins; Uri Tabori
Journal:  Childs Nerv Syst       Date:  2016-09-20       Impact factor: 1.475

Review 10.  The mTOR signaling pathway as a treatment target for intracranial neoplasms.

Authors:  Doreen Pachow; Wolfgang Wick; David H Gutmann; Christian Mawrin
Journal:  Neuro Oncol       Date:  2014-08-27       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.